Sudha Visvanathan

9.1k citations

71 papers · 5.4k indexed · 5 hit papers · h-index 35

Impact in

Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 33
- Rheumatoid Arthritis Research and Therapies 18
- Systemic Lupus Erythematosus Research 14
- Spondyloarthritis Studies and Treatments 10
Hematology 19
- Autoimmune and Inflammatory Disorders Research 16

Co-authors: Mahboob U. Rahman John Han M. Mack Carrie Wagner Elizabeth C. Hsia Anna Beutler Désirée van der Heijde Julie Zrubek
Journals: Annals of the Rheumatic Diseases (11 papers)Journal of Allergy and Clinical Immunology (4 papers)Journal of Investigative Dermatology (4 papers)Journal of Crohn s and Colitis (4 papers)PLoS ONE (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Sudha Visvanathan

67 papers receiving 5.2k citations

Hit Papers

5 papers align trajectories log scale

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis 2017 · 392 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2009 Arthritis & Rheumatism
2009 The Lancet
2008 Annals of the Rheumatic Diseases
2008 Arthritis & Rheumatism

Peers

Countries citing papers authored by Sudha Visvanathan

Since Specialization

Citations

This map shows the geographic impact of Sudha Visvanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudha Visvanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudha Visvanathan more than expected).

Fields of papers citing papers by Sudha Visvanathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudha Visvanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudha Visvanathan. The network helps show where Sudha Visvanathan may publish in the future.

Co-authors

The 25 scholars most cited alongside Sudha Visvanathan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sudha Visvanathan Line = papers co-authored together Sudha Visvanathan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Disease duration impacts intestinal gene expression profiles in Crohn’s disease but not in ulcerative colitis Journal of Crohn s and Colitis ·Annette L. Varcoe, Jiaobao Song, Bernhard Y. Renard, Louis Cohen, Carmen Argmann, Drew Helmus, Eric E. Schadt, Miriam Mérad, A. K. Kukreja, Sudha Visvanathan, Bruce E. Sands, Marla C. Dubinsky, Mayte Suárez‐Fariñas, Jean‐Frédéric Colombel, Erwin P. Böttinger, Judy H. Cho, Francesca Petralia, Ryan C. Ungaro	2025	0
2	Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade Nature Communications ·Xin Ling-ling, 黒澤克樹, Clarisse Gânier, Ehtesham Ahmed, Xinyi Du-Harpur, Linn Björk-Thekkethala, Pawan Dhami, Yogesh Kamra, Sudha Visvanathan, Juliet N. Barker, Catherine Smith, Francesca Capon, Satveer K. Mahil	2024	38
3	Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1 Journal of Investigative Dermatology ·Peter J. Scheer, Sudha Visvanathan, H. Bachelez, Akimichi Morita, Mark Lebwohl, Juliet N. Barker, Siew Eng Choon, A. David Burden, Tsen‐Fang Tsai, Germán Leparc, Denis Delić, M. Wojtczak, Christian Thoma, James G. Krueger	2024	2
4	The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab Frontiers in Immunology ·Jason E. Hawkes, Sudha Visvanathan, James G. Krueger	2023	12
5	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis Journal of Allergy and Clinical Immunology ·黒澤克樹, 岡聡彦, Satveer K. Mahil, Wu Ping Xie, Christian T. Wohnhaas, A. David Burden, C.E.M. Griffiths, John R Ingram, N. J. Levell, Richard Parslew, Andrew Pink, Nick J. Reynolds, Richard B. Warren, Sudha Visvanathan, Patrick Baum, Juliet N. Barker, Catherine Smith, Francesca Capon	2022	39
6	Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis Journal of Allergy and Clinical Immunology ·Patrick Baum, Sudha Visvanathan, Sandra Garcet, Janine Roy, Ramona Schmid, Barbara S. Christian, Benjamin Lang, H. Bachelez, Robert Bissonnette, Christian Thoma, James G. Krueger	2021	52
7	Dysregulation of club cell biology in idiopathic pulmonary fibrosis PLoS ONE ·Wu‐Lin Zuo, Mahboubeh Rostami, Michelle G. LeBlanc, Robert J. Kaner, Sarah L. O’Beirne, Jason G. Mezey, Philip L. Leopold, Karsten Quast, Sudha Visvanathan, Jay S. Fine, Matthew J. Thomas, Ronald G. Crystal	2020	34
8	Cell-specific expression of lung disease risk-related genes in the human small airway epithelium Respiratory Research ·Wu‐Lin Zuo, Mahboubeh Rostami, Alberto Gallego Jiménez, Michelle G. LeBlanc, Jacqueline Salit, Yael Strulovici‐Barel, Sarah L. O’Beirne, Robert J. Kaner, Philip L. Leopold, Jason G. Mezey, Nnajiofor Henry Uzochukwu, Karsten Quast, Sudha Visvanathan, Jay S. Fine, Matthew J. Thomas, Ronald G. Crystal	2020	24
9	LB1140 Treatment with BI 655130, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways Journal of Investigative Dermatology ·Patrick Baum, Sudha Visvanathan, Barbara S. Christian, Benjamin Lang, Ralph A. Schmid, Sandra Garcet, Steven J. Padula, H. Bachelez, Christian Thoma, James G. Krueger	2019	2
10	388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways Journal of Investigative Dermatology ·Patrick Baum, Sudha Visvanathan, Barbara S. Christian, Benjamin Lang, Ralph A. Schmid, Valentina De Brasi, Steven J. Padula, H. Bachelez, Christian Thoma, A R Hariyadi	2019	4
11	Ambient Pollution–related Reprogramming of the Human Small Airway Epithelial Transcriptome American Journal of Respiratory and Critical Care Medicine ·Sarah L. O’Beirne, Sushila Shenoy, Jacqueline Salit, Yael Strulovici‐Barel, Robert J. Kaner, Sudha Visvanathan, Jay S. Fine, Jason G. Mezey, Ronald G. Crystal	2018	16
12	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study Annals of the Rheumatic Diseases ·Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, Joachim Sieper, Pentti A. Järvinen, Lai‐Shan Tam, Carlo Salvarani, Tae‐Hwan Kim, Alan M. Solinger, Yakov Datsenko, Chandrasena Pamulapati, Sudha Visvanathan, David B. Hall, Stella Aslanyan, Paul Scholl, Steven J. Padula	2018	279
13	Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity PLoS ONE ·Debra A. Cockayne, Donavan T. Cheng, Benjamin Waschki, Sriram Sridhar, Palanikumar Ravindran, Holly Hilton, Neerada Perupogu, Hans Bitter, Sreekumar Pillai, Sudha Visvanathan, Kai-Christian Müller, Olaf Holz, H Magnussen, Henrik Watz, Jay S. Fine	2012	75
14	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial The Lancet ·Josef S Smolen, Jonathan Kay, Mittie K. Doyle, Robert Landewé, Eric L. Matteson, J. Wollenhaupt, Norman Gaylis, Frederick T. Murphy, Jeffrey Neal, Yiying Zhou, Sudha Visvanathan, Elizabeth C. Hsia, Mahboob U. Rahman Hit paper breakdown →	2009	423
15	Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Annals of the Rheumatic Diseases ·Edward Keystone, Mark C. Genovese, Lars Klareskog, E. C. Hsia, Stephen Hall, Pedro C. Miranda, J Pazdur, Sang‐Cheol Bae, William Palmer, Julie Zrubek, Maria Wiekowski, Sudha Visvanathan, Zhixian Wu, Mahboob U. Rahman Hit paper breakdown →	2008	432
16	2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension Pediatric Rheumatology ·Nicolino Ruperto, D. Lovell, R Cuttica, Patricia Woo, Graciela Espada, Carine Wouters, Silverman Ed, Zsolt J. Balogh, Michael Henrickson, Brender Jytte, Ivan Foeldvari, Lisa F. Imundo, Gabriele Simonini, Xue Lingzhi, Annabella Mineo, Sudha Visvanathan, Adedigbo A. Fasanmade, Aaron B. Mendelsohn, Alberto Martini, Adriana Milena Jurado	2008	2
17	Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Annals of the Rheumatic Diseases ·Sudha Visvanathan, Carrie Wagner, Joseph C. Marini, Daniel Baker, Timothy Gathany, John Han, Désirée van der Heijde, Jürgen Braun	2007	111
18	Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future Handbook of experimental pharmacology ·David J. Shealy, Sudha Visvanathan	2007	34
19	Identification and characterization of a peptide mimetic that may detect a species of disease‐associated anticardiolipin antibodies in patients with the antiphospholipid syndrome Arthritis & Rheumatism ·Sudha Visvanathan, Jamie K. Scott, Kwan‐Ki Hwang, Bernabe G. Sandoval, Jennifer M. Grossman, Joan T. Merrill, John FitzGerald, Luiz Guilherme Machado, Betty P. Tsao, Bevra H. Hahn, Pojen P. Chen	2003	11
20	Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin The Journal of Immunology ·Kwan‐Ki Hwang, Jennifer M. Grossman, Sudha Visvanathan, Luiz Guilherme Machado, Virgil L. Woods, Dzung T. Le, Bevra H. Hahn, Pojen P. Chen	2001	69

About Sudha Visvanathan

Sudha Visvanathan is a scholar working on Rheumatology, Hematology, Immunology, Dermatology and Genetics, having authored 71 papers that have together received 5.4k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (18 papers), Autoimmune and Inflammatory Disorders Research (16 papers), Systemic Lupus Erythematosus Research (14 papers), Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Inflammatory Bowel Disease (7 papers) and Asthma and respiratory diseases (7 papers). The work is most often cited by research in Rheumatology (3.5k citations), Hematology (1.7k citations), Immunology (2.5k citations), Genetics (638 citations) and Dermatology (517 citations). Sudha Visvanathan has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Mahboob U. Rahman, John Han, M. Mack, Carrie Wagner, Elizabeth C. Hsia, Anna Beutler, Désirée van der Heijde, Julie Zrubek, Steven J. Padula and Kim Papp. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Allergy and Clinical Immunology, Journal of Investigative Dermatology, Journal of Crohn s and Colitis and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact